News in brief: AstraZeneca, Pure Gym, Galliford, Publishing Technology, Shoe Zone, RM2
AstraZeneca is 'too pricey'Analysts at investment bank Goldman Sachs say long-term estimates for pharmaceutical firm AstraZeneca (AZN) are too optimistic and the equity valuation too full. The bank's rating on the stock is cut from...
14 April 2016